April 2017: TheraSource received a $333,340 STTR Phase I grant to develop TSA521 as a new therapy for sepsis and inflammation.
November 2016: TheraSource received a $1.5 million SBIR Phase II grant to develop human ghrelin and human growth hormone combination therapy as a new treatment for sepsis in the elderly.
July 2016: TheraSource received a $335,318 SBIR Phase I grant to develop rhMFG-E8 as a new treatment for acute kidney injury (AKI).
July 2016: TheraSource participated in the workshop “Medical Management of Radiation Casualties: Where Research and Usage Meet”, organized jointly by the National Institute of Allergy and Infectious Diseases (NIAID) and the Radiation Injury Treatment Network (RITN) (Rockville, MD).
May 2016: TheraSource received a $3 million SBIR Phase II grant to develop human ghrelin as an acute radiation injury mitigator.
January 2016: TheraSource received an SBIR Phase I grant to develop rhMFG-E8 as an adjuvant therapy for hemorrhagic shock.
January 2016: TheraSource published the article "Combined administration of human ghrelin and human growth hormone attenuates organ injury and improves survival in aged septic rats." MolMed 2016; 22:124-35.
November 2015: TheraSource was invited to exhibit our technology at the 2015 Life Sciences Summit (New York, NY).
September 2015: TheraSource was selected to exhibit our technology as part of the Innovation Challenge for the Redefining Early Stage Investments meeting (RESI; Boston, MA).
July 2015: TheraSource presented at the New York-Beijing Bioforum, in New York City.
July 2015: TheraSource was featured in the BioPharm Insight article: "TheraSource seeks pharma partner, CMO for acute kidney injury drug - executives".
June 2015: Ping Wang, TheraSource founder and CEO, has been elected president of the Shock Society. Feinstein Institute Researcher is Elected President of Shock Society.
June 2015: TheraSource has been selected to exhibit and showcase our technology in the National Institutes of Health Innovation Zone at the Biotechnology Industry Organization (BIO) International Convention 2015, Philadelphia, June 15-18.
May 2015: TheraSource presented at Brain Tumor Biotech Summit 2015 on May 29 (New York, NY).
May 2015: TheraSource was invited to present in Pitch & Partner Forum at the New York BIO 2015 Annual Conference on May 4-5, New York City.
March 2015: TheraSource published the article "Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice." Lab Invest, 2015, 95:480-90.
February 2015: TheraSource published the article “Human ghrelin mitigates intestinal injury and mortality after whole body irradiation in rats." PLoS One 2015, 10:e0118213.
October 2014: TheraSource was selected to participate in National Institutes of Health Commercialization Assistance Program (NIH-CAP).
October 2014: TheraSource presented a poster at the Life Sciences Summit 2014 in New York City.
June 2014: TheraSource received two SBIR Phase I grants, “A Novel Recombinant Protein for Mitigating Total Body Radiation Injury” and “Ghrelin for Stroke”.
May 2014: TheraSource was invited to present “rhMFG-E8 for sepsis treatment” to potential investors and partners in Boston by The National Heart, Lung, and Blood Institute’s Office of Translational Alliances as well as in Long Island, New York by Long Island Capital Alliance.
February 2013: TheraSource received a SBIR Phase II Contract “rhMFG-E8 for Alcohol-induced Tissue Injury and Infections” from NIH/NIAAA.